International AIDS Vaccine Initiative
IAVI is a nonprofit scientific research organization dedicated to developing vaccines and antibodies for HIV, tuberculosis, and emerging infectious diseases. Their mission is to translate scientific discoveries into affordable, globally accessible public health solutions, aiming for a world where all people have equitable access to innovative vaccines and therapeutics.
Industries
N/A
Products
Replicating viral-vector vaccine candidates for hemorrhagic and emerging viruses
Clinical- and preclinical-stage vaccine candidates developed using replicating viral-vector platforms for pathogens such as Lassa fever, Ebola and Marburg viruses, and SARS-CoV-2; advanced into preclinical testing and clinical evaluation depending on candidate.
Live-attenuated and nucleic-acid tuberculosis vaccine candidates
Tuberculosis vaccine candidates including live-attenuated constructs and nucleic-acid-encoded antigen constructs advanced in preclinical and clinical development to improve protection in adolescents and adults.
Germline-targeting immunogen candidates delivered via nucleic-acid and nanoparticle platforms
Engineered immunogens designed to engage precursor B cells delivered in nucleic-acid or protein nanoparticle formats and evaluated in clinical studies to prime broadly neutralizing antibody lineages.
Replicating viral-vector vaccine candidates for hemorrhagic and emerging viruses
Clinical- and preclinical-stage vaccine candidates developed using replicating viral-vector platforms for pathogens such as Lassa fever, Ebola and Marburg viruses, and SARS-CoV-2; advanced into preclinical testing and clinical evaluation depending on candidate.
Live-attenuated and nucleic-acid tuberculosis vaccine candidates
Tuberculosis vaccine candidates including live-attenuated constructs and nucleic-acid-encoded antigen constructs advanced in preclinical and clinical development to improve protection in adolescents and adults.
Germline-targeting immunogen candidates delivered via nucleic-acid and nanoparticle platforms
Engineered immunogens designed to engage precursor B cells delivered in nucleic-acid or protein nanoparticle formats and evaluated in clinical studies to prime broadly neutralizing antibody lineages.
Services
Product development center services
End-to-end translational development support including program management, process development for clinical manufacturing, regulatory strategy, and coordination with manufacturing and clinical partners to advance vaccine and antibody candidates.
Clinical trial design and operations
Protocol development, site management, clinical monitoring, safety oversight, data management, biostatistics, and medical writing for Phase I–IV vaccine and antibody clinical trials, including discovery-medicine and iterative prime-boost trial designs.
Epidemiology, surveillance, and evidence synthesis
Design and execution of observational cohorts, incidence and prevalence studies, surveillance programs, systematic reviews, meta-analyses, and modeling to inform target selection, trial site choice, and to evaluate assay performance for prevalence estimates.
Antibody discovery and translational laboratory services
Screening, isolation, characterization, and preclinical optimization of monoclonal antibodies using cohort samples and high-throughput laboratory platforms; support for advancing antibodies toward clinical testing.
Global access, implementation research, and health economics
End-user research, socio-behavioral studies, health economic analyses, and demand forecasting to inform introduction strategies, procurement decisions, and equitable access planning for vaccines and biologics.
Capacity strengthening and technology transfer programs
Partnerships and programs to build regional laboratory and clinical research capacity, train scientists and operational staff, and facilitate collaborations with regional manufacturers to enable local development and production.
Product development center services
End-to-end translational development support including program management, process development for clinical manufacturing, regulatory strategy, and coordination with manufacturing and clinical partners to advance vaccine and antibody candidates.
Clinical trial design and operations
Protocol development, site management, clinical monitoring, safety oversight, data management, biostatistics, and medical writing for Phase I–IV vaccine and antibody clinical trials, including discovery-medicine and iterative prime-boost trial designs.
Epidemiology, surveillance, and evidence synthesis
Design and execution of observational cohorts, incidence and prevalence studies, surveillance programs, systematic reviews, meta-analyses, and modeling to inform target selection, trial site choice, and to evaluate assay performance for prevalence estimates.
Antibody discovery and translational laboratory services
Screening, isolation, characterization, and preclinical optimization of monoclonal antibodies using cohort samples and high-throughput laboratory platforms; support for advancing antibodies toward clinical testing.
Global access, implementation research, and health economics
End-user research, socio-behavioral studies, health economic analyses, and demand forecasting to inform introduction strategies, procurement decisions, and equitable access planning for vaccines and biologics.
Capacity strengthening and technology transfer programs
Partnerships and programs to build regional laboratory and clinical research capacity, train scientists and operational staff, and facilitate collaborations with regional manufacturers to enable local development and production.
Expertise Areas
- Vaccine and antibody discovery
- Monoclonal antibody isolation and engineering
- Preclinical models and challenge studies (small animals and nonhuman primates)
- Clinical trial design and operations, including discovery-medicine trials
Key Technologies
- Replicating viral-vector vaccine platforms
- mRNA lipid nanoparticle (mRNA-LNP) vaccine platforms
- Protein nanoparticle display for immunogen multivalency
- High-resolution structural biology (cryo-electron microscopy)